Eclosion Emerges to Fill A Swiss Start-Up Void
This article was originally published in Start Up
Executive Summary
Despite being home to renowned research institutions and universities and mid- to large-size biopharma companies, Geneva, Switzerland, midway through the last decade, still lacked what it considered a vibrant life sciences start-up scene. A few years later and the Swiss region’s all-hands-on deck approach to building one has birthed a new hybrid model, the public/private endeavor Eclosion, which is one part early-stage incubator and another part venture fund.
You may also be interested in...
Red Script Ventures : Another addition to Johnson & Johnson's early stage R&D tool-box
Red Script is a business accelerator whose purpose is to make early stage investments--either seed or Series A-- in companies developing riskier, but potentially transformative-types of science, such as regenerative medicine or neurostimulation.
Corporate Biotech Incubators
Corporate incubators at Pfizer and Biogen--designed to provide a supply of strategically aligned biotech assets to the parent pipeline--remain unproven. But they're among a range of experiments aimed at helping seed discovery-stage ventures
Hijacking The Messenger
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.